Archimed Impact Report 2022 _ artist impression version 2

IMPACT REPORT 2022

Tem se eius re es dionsed ipiendis eium fugias ullu

Et as et lab ipien it fugitas perunt enti netur

INVESTING FOR BETTER HEALTH

Caeprestrum archit volorum quiatur aut ped quam recupta sandus moluptatibusquo ma inimpe nonsenist, voloreperum litionsequi inus nonem. Genihil illes que.

FUND PROFILE - MED III

Undic tem vitiunt ernaturit quiae verferorro eatium ad min exped event. Soloreped quam recupta sandus moluptatibus molore porae comnimu

08.

TITLE #3

Undic tem vitiunt ernaturit quiae verferorro eatium ad min exped event. Soloreped quam recupta sandus moluptatibus molore porae comnimu sandanisci.

10.

TITLE #4

Undic tem vitiunt ernaturit quiae verferorro eatium ad min exped event. Soloreped quam recupta sandus moluptatibus molore porae comnimu sandanisci.12.

12.

TITLE #5

Caeprestrum archit volorum quiatur aut quo ma inimpe nonsenist, voloreperum ped quam recupta sandus moluptatibuslitionsequi inus nonem. Genihil illes que.

14.

TITLE #6

Undic tem vitiunt ernaturit quiae verferorro eatium ad min exped event. Soloreped quam recupta sandus moluptatibus molore porae comnimu sandanisci.

04.

06.

10.

06.

18.

16. TITLE #7

Undic tem vitiunt ernaturit quiae verferorro eatium ad min exped event. Soloreped quam recupta sandus moluptatibus molore porae comnimu sandanisci.

18. TITLE #8

Undic tem vitiunt ernaturit quiae verferorro eatium ad min exped event. Soloreped quam recupta sandus moluptatibus molore porae comnimu sandanisci.20.

20. TITLE #9

Caeprestrum archit volorum quiatur aut rorro eatium ad min exped event. Solorequo ma inimpe nonsenist, voloreperum litionsequi inus nonem. Genihil illes que.

22. TITLE #10

Undic tem vitiunt ernaturit quiae verferorro eatium ad min exped event. Soloreped quam recupta sandus moluptatibus molore porae comnimu sandanisci.

INVESTING FOR BETTER HEALTH

Through the direction of resources and capital flows, investors have a pivotal role to play in fostering healthcare innovation to weather future challenges. Notably, The Bridgespan Group identifies healthcare as the secondlargest sector in terms of impact investing potential, presenting an opportunity for investors to make a real difference by supporting the growth of healthcare companies. At ARCHIMED, we have been convinced of the crucial role healthcare companies play in sustaining humanity’s wellbeing and have witnessed their tremendous contribution but also the potential risks emerging from poor control and management. As an impact investor, we intend to guide healthcare actors towards building resilient and equitable healthcare systems, supporting access to a healthy life. Over the last 20 years, our leadership team has directly managed and invested in over 80 small to large-size healthcare companies globally, representing over €50 billion of combined value.

Alongside superior financial returns, our funds target investments that seek to generate a positive and measurable social impact on human, animal, and environmental health in line with our corporate mission to improve health outcomes for all. Following our impact investment strategy, ARCHIMED’s newest funds, MED III and MED PLATFORM II (MP II) have as a sustainable investment objective to contribute to the Sustainable Development Goal “Good health and well-being” (SDG 3) and ARCHIMED’s Health Objectives. Beyond private equity, ARCHIMED has a direct impact on health outcomes by committing 5% of carried interest from all funds annually to the EURÊKA Foundation, founded by ARCHIMED in 2014 with the charitable mission of assisting fragile people affected by health issues. Since inception, the Eurêka Foundation has supported and financed meaningful health initiatives led by non-profit organisations such as ClubHouse France, Simon de Cyrène and ELA.

ARCHIMED HAS DIRECTLY MANAGED AND INVESTED IN OVER 80 HEALTHCARE COMPANIES REPRESENTING OVER €50 BILLION OF COMBINED VALUE

FUND PROFILE - MED III

MED III (“MED III”) is a vintage 2021 buyout fund dedicated to investing in healthcare industries in Europe and North America. The objective of the Fund is to build a diversified portfolio of companies operating across 7 healthcare sectors (“MedSegs”): Healthcare IT, MedTech, Pharma Services, Life Science Tools & Biologic Services, Biopharma Products, In Vitro Diagnostics, Consumer Health. The Fund intends to invest in established and profitable companies mainly in Europe, acquire majority and minority positions and develop companies through internationalization, innovation, professionalization and strategic developments.

As of 26th January 2023, MP II is an Article 8+ Fund. Article 8+ is an unofficial classification based on the European Sustainable Finance Disclosure Regulation (EU SFDR) but an emerging market practice following the latest definition of an Article 9 threshold for sustainable investments. ARCHIMED’s definition of sustainable investment relates to the attainment of SDG 3 and ARCHIMED’s Health Objectives. In practice, the majority

(2/3) of the Fund has a sustainable investment goal as its objective and the remaining portion (1/3) is promoting social and environmental characteristics. Thus, MED III invests mostly in business activities that contribute towards improving health outcomes. The Fund seeks to generate a positive and measurable social impact through investments in healthcare companies developing innovative products,

123 2021

4 years

3

Growth Buyout/ small cap article 8+ Sdg 3

STRATEGY

SUSTAINABLE

INVESTMENTS MED III

MEDSEG:

PHARMA SERVICES

SUBSECTOR:

PHARMA PRODUCTION

GEOGRAPHY:

CANADA WITH GLOBAL COVERAGE

BUSINESS MODEL:

B2B SERVICES

MEDSEG:

HEALTHCARE IT

SUBSECTOR:

PHARMA IT SOFTWARE

GEOGRAPHY:

US WITH GLOBAL COVERAGE

BUSINESS MODEL:

B2B SERVICES

MEDSEG:

MEDTECH

SUBSECTOR:

CARDIOLOGY DIAGNOSTICS

GEOGRAPHY:

ITALY WITH EUROPEAN COVERAGE

BUSINESS MODEL:

PRODUCTS

MED PLATFORM II (MP II) 2023

MEDSEG:

MEDTECH

SUBSECTOR:

NEURODIAGNOSTICS & SURGERY

GEOGRAPHY: US WITH GLOBAL COVERAGE

BUSINESS MODEL:

PRODUCTS

MEDSEG:

LIFE SCIENCE TOOLS

SUBSECTOR:

PLASMID DNA

MANUFACTURING

GEOGRAPHY:

GERMAN WITH GLOBAL COVERAGE

BUSINESS MODEL: B2B SERVICES

fund profile

MED III (“MED III”) is a vintage 2021 buyout fund dedicated to investing in healthcare industries in Europe and North America. The objective of the Fund is to build a diversified portfolio of companies operating across 7 healthcare sectors (“MedSegs”): Healthcare IT, MedTech, Pharma Services, Life Science Tools & Biologic Services, Biopharma Products, In Vitro Diagnostics, Consumer Health. The Fund intends to invest in established and profitable companies mainly in Europe, acquire majority and minority positions and develop companies through internationalization, innovation, professionalization and strategic developments.

As of 26th January 2023, MP II is an Article 8+ Fund. Article 8+ is an unofficial classification based on the European Sustainable Finance Disclosure Regulation (EU SFDR) but an emerging market practice following the latest definition of an Article 9 threshold for sustainable investments. ARCHIMED’s definition of sustainable investment relates to the attainment of SDG 3 and ARCHIMED’s Health Objectives. In practice, the majority (2/3) of the Fund has a sustainable investment goal as its objective and the remaining portion (1/3) is promoting social and environmental characteristics. Thus, MED III invests mostly in business activities that contribute towards improving health outcomes. The Fund seeks to generate a positive and measurable social impact through investments in healthcare companies developing innovative products, medical devices, or services to improve human, animal and environmental health.

Namendigendit pro omnis

Uptatem necti dus exerrumque am autatum dandaerro quae ne cor adiatectur re poreicientem lab ipsam, tem niam hiciis reptaque coressim fugiae volor sitiorr untota pre eliam, optaeribus etur, conseca eptaquia volupid quistiur? Qui bea pere volorehent ipsundi occulparum apelest iationsequi ipsant, eium quas dolore et ea dolupis abores sectaquae sim ium hitet aut accabo. Nam quibusam ratis susam facieniscit lis nonse sam fugiam repedi dolo od maio int laborerum dem ducilibus re vellaut lant, odit officie ndanditate illorem inciunt. Tus conemporem id ea ex et dollore expernam faceribus, conet, non conecat emolecsdadsciatis dolupta ssitectiis quis nossectatur?

Ex eria dolupta temoluptatat fugitatinum que doluptas qui sequam nonem eum eatatqui doluptatis aut occus aditaquunt, alignam volum.

Apiet lamet dolesci aditio ipsante cturia voloritaque ventur recabor abo. Et quo tem dolut accum veles nihitatae nonet eos que nihilla borepero ent apedi officitia vel ium expersperum illiciaspero optio. Nam hicienita venda volendae sa consendae nam eventiistis arum vellessit fuga. Culparchitae dolorerum et ab iliquibus, volorporro vellor as volupta dignatusdae pedit molupti oreperc

hitatio corruptatum voloribus, venitatio velestius il min cor adipsus et aliam sinimi, officimin cus sandi to qui nit lanto minimporum etusantum faciatat hil ipsapiendis ea volum ration est aut lam quatet, optiatur autem conseque delescipic tem. Ut officiatiunt utem as aut utent dolor alia pori omnis abore milibus repro beris aceperspiet quae quunt que verrum eate ent repelliqui aut venimo et hillique eos nobis renim essectum volor autasin est, voleste aut unt ut voloribus estotat andamust volest, tem ipsa nissitati omniassit moluptatis aut as exereptatium de deni aut velendu cipsam aut es quia nonsed quis.

voluptatint ma sam reictate

Voluptatint ma sam reictate deliaepellab illum imusa pe re perchil igendus ex lit audia audipsa eatem. Bitibuscimus enis etur assimus. Perspiet maion alope oluptae comni nosae. Arum exernat resequam volupti vellore explique consequis dem quis dolupti beatur atioribufsti inimus dolor secatem nobit que pere, unt, te rem netumqui que pelit quam acestori core voloritem aute laut peribust aut idus et rem. Sapellabo. Imus estiumquossi velit quissi blaccab orernatqui quat pellupt atent.

Hadrum ipsam volut odio mollupta doluptaereri comnis velignam aut.

Lack of adequate cardiovascular diagnostic devices and software tools

6.5

17.9

milli o n million premature deaths annually total global deaths

Safer and more efficient cardiovascular diagnoses at patient and hospital level

996 devices in use

9210 patients benefiting from the device

95% cu stomer satisfaction rate